- Conditions
- Healthy Adult Subjects
- Interventions
- Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- COVID-19
- Interventions
- Losmapimod oral tablet, Placebo oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Irvine, California • Miami, Florida • Tampa, Florida + 2 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 3,503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 91
- States / cities
- Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Losmapimod, Placebo oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more
- Conditions
- Glomerulosclerosis, Focal Segmental
- Interventions
- Losmapimod
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Losmapimod oral tablet, Placebo oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more